Posted on 10/5/17
Johnson & Johnson And The Bull Case
Photo creditJohnson & Johnson (JNJ) was a stock I was reluctant to back in the past few years. The valuation didn’t quite seem to fit for . . .
Posted on 10/5/17
Teva Receives Big Blow On Generics Pricing
Teva (TEVA) continues to remain in a bind, and I have mentioned on many occasions why the name should be shorted. Well, things are about to . . .
Posted on 10/5/17
Teva - Copaxone Competition Comes At The Worst Time
Teva Pharmaceuticals (TEVA) is back to square one as it got hit by some bad news at an unfortunate point in time. Competitor Mylan (MYL) is . . .
Posted on 10/4/17
Rare Disease Report and CURE Magazine Welcome the Fibrolamellar Cancer Foundation as a Strategic Alliance Partner
CRANBURY, N.J.--(BUSINESS WIRE)--Rare Disease Report® (RDR®) and CURE® magazine have joined forces with the Fibrolamellar Cancer Foundation (FCF) through the Strategic Alliance Partnership (SAP) program, announced . . .
Posted on 10/4/17
2 Clear-Cut Reasons Teva Pharmaceutical Industries Tacked on $1.3 Billion in Market Cap in September
What happenedShares of Teva Pharmaceutical Industries (NYSE:TEVA), an Israeli-based developer of branded and generic drugs, gained more than 8% during September, totaling $1.3 billion in market . . .
Posted on 10/4/17
Johnson & Johnson: Best of Breed in Healthcare
Johnson & Johnson (JNJ) is considered by many to be one of the best long-term stocks, due to its consistent high performance throughout many decades of . . .
Posted on 10/4/17
Is This How Drugmakers Will Kill Biosimilars?
Pfizer (NYSE:PFE) has filed a lawsuit accusing Johnson & Johnson (NYSE:JNJ) of strong-arming insurers into excluding its Remicade biosimilar, Inflectra, from their reimbursement lists. If drugmakers . . .
Posted on 10/3/17
Pfizer: A Good Buy
I find Pfizer (PFE) a truly wonderful business. The reason for this is because the company is able to present its investors year after year with . . .
Posted on 10/3/17
More Proof Pfizer's Dividend Is The Only Reason To Own It
Photo creditPfizer (PFE) shares never seem to go anywhere despite the company's enormous R&D budget and equally impressive acquisitions. That's interesting but given the tremendous pace . . .
Posted on 10/3/17
Celgene Could Be A $200 Stock
Since its spin-off from Celanese in 1986, Celgene (CELG) has built an active pipeline of drugs that focus on treatments for cancer and inflammatory diseases. Additionally, . . .
Posted on 10/3/17
Best Buy: Johnson & Johnson, Pfizer, or Gilead Sciences?
Remember the old game show "Let's Make a Deal"? It was originally hosted by the recently deceased Monty Hall, and its current iteration is hosted by . . .
Posted on 10/3/17
Better Buy: Gilead Sciences, Inc. vs. Pfizer
The biopharmaceutical industry has been exceptionally kind to investors over the past six years because of the introduction of several new classes of drugs, greater insurance . . .
Posted on 10/2/17
Pfizer Exposes the Sordid Underbelly of Drug Prices
Johnson & Johnson's (NYSE:JNJ) one of the largest drugmakers in the world, and according to a lawsuit Pfizer (NYSE:PFE) has filed, it's leveraging its size to . . .
Posted on 10/2/17
Best Buy: Johnson & Johnson, Pfizer, or Gilead Sciences?
Remember the old game show "Let's Make a Deal"? It was originally hosted by the recently deceased Monty Hall, and its current iteration is hosted by . . .
Posted on 9/29/17
Johnson & Johnson Is A Buy - Cramer's Lightning Round (9/27/17)
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Wednesday, September 27.Bullish CallsJohnson & Johnson (NYSE:JNJ): Buy half at current price and . . .
Posted on 9/29/17
Celgene Presents Strong Potential Despite Clinical Hold Setback
Celgene Corporation (NASDAQ:CELG) has four products that together make around $3 billion per quarter - these are, Revlimid at $2bn, and Pomalyst/Imnovid, the two iMiDs or . . .
Posted on 9/28/17
Johnson & Johnson Investors, Mark Your Calendars for October
After a nice jump in the first half of 2017, Johnson & Johnson (NYSE:JNJ) stock has largely tread water over the last few months. Wouldn't it . . .
Posted on 9/27/17
Bellerophon Announces $23 Million Private Placement
WARREN, N.J., Sept. 27, 2017 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, announced today that it has entered into a definitive securities . . .
Posted on 9/27/17
Pfizer's Loss Of Exclusivity Is Exaggerated
Concerns about LOE, or loss of exclusivity, and lack of revenue growth at Pfizer (PFE) are vastly overblown. The company is set to grow in the . . .
Posted on 9/27/17
Celgene's (CELG) Management Presents at Cantor Fitzgerald 3rd Annual Healthcare Conference (Transcript)
Celgene Corporation (NASDAQ:CELG)Cantor Fitzgerald 3rd Annual Healthcare ConferenceSeptember 26, 2017 09:45 A.M. ETExecutivesNadim Ahmed - President, Hematology and OncologyAnalystsMara Goldstein - Cantor FitzgeraldUnidentified Analyst -Mara GoldsteinHi, . . .
Posted on 9/27/17
LIA Diagnostics, ImmERge Labs Join Science Center Health Accelerator
It’s been quite a year for scientist Marion Leary. First, her startup ImmERge Labs spun out from Penn, kicking
Posted on 9/26/17
Johnson & Johnson Is Not A Good Buy
By applying different what-if scenarios to Johnson & Johnson (JNJ), I arrived at a conclusion that a fair value would be more likely in the 70$ . . .
Posted on 9/26/17
Pfizer's Ibrance To Rally Share Price Past $40
Shares of Pfizer Inc. (NYSE:PFE) are finally starting to catch a bid which is encouraging. Shares have been pretty much range bound for the past 24 . . .
Posted on 9/26/17
Johnson & Johnson Vs. Pfizer: Which Is A Better Buy?
Investment ThesisBoth Pfizer (PFE) and Johnson & Johnson (JNJ) are among the leading pharmaceutical companies in the world where J&J’s business also extends to consumer health . . .
Posted on 9/26/17
CURE Media Group Expands Strategic Alliance Partnership Program With The National Pancreas Foundation
CRANBURY, N.J.--(BUSINESS WIRE)--CURE Media Group proudly announces the addition of The National Pancreas Foundation (NPF) to its Strategic Alliance Partnership Program (SAP program). The collaboration will . . .

